Reproductive Technology and IVF: What Four Perspectives Are Protecting

A couple in their mid-thirties spent four years trying to conceive. Two rounds of intrauterine insemination failed. Three IVF cycles followed — the first two producing embryos that did not implant, the third producing the daughter who is now two years old and learning to name colors. The couple does not think of themselves as having done something controversial. They think of themselves as having wanted a family and having gotten medical help to start one. The $60,000 they spent — partly covered by insurance, partly borrowed from family — does not feel like a philosophical statement. It feels like the cost of the most important thing in their lives.

A genetic counselor who has spent fifteen years working with families navigating prenatal diagnosis has a more complicated relationship with the technology. She has a son with Down syndrome who is eleven years old, plays soccer, and has a best friend he calls every day after school. Her work regularly involves supporting families through decisions about preimplantation genetic testing — embryo selection that screens out chromosomal differences like his. She does not tell families what to do. But she is aware that the normalized use of this technology sends a message about which lives are worth beginning. She is not against IVF. She is not sure what she is for.

Both families are living inside a technology that has produced five million births worldwide since Louise Brown in 1978, that is now involved in roughly 2 percent of all births in the United States, and that sits at the intersection of five genuinely distinct ethical disputes: about the moral status of embryos, about reproductive liberty, about genetic selection and disability, about equity of access, and about the kinds of families and futures that medicine is in the business of enabling. These disputes do not resolve into a single argument.

What reproductive autonomy advocates are protecting

The case for assisted reproduction as an extension of reproductive liberty begins with the claim that the decision to have a child — and the decision about how to go about it — is among the most intimate and fundamental choices a person can make. That claim has real things to protect.

It is protecting the right to build a family by available means. John Robertson, in Children of Choice: Freedom and the New Reproductive Technologies (Princeton University Press, 1994), argues that procreative liberty — the freedom to decide whether and when and how to reproduce — is a fundamental right, one that government should not restrict without compelling justification. This right does not stop at the bedroom door. If a couple cannot conceive without medical help, refusing to recognize IVF as a legitimate medical intervention is not a neutral position. It is a decision to deny them something that couples who conceive naturally take for granted. The harm principle cuts against restriction, not toward it: whose interests are being protected by making IVF unavailable, unaffordable, or legally precarious?

It is protecting equal treatment for infertility as a medical condition. The World Health Organization classifies infertility as a disease of the reproductive system. Insurance coverage that pays for treating one reproductive condition while excluding infertility treatments treats similarly situated patients unequally. As of 2024, nineteen U.S. states require some form of IVF insurance coverage; the majority do not. The result is a two-tier system in which the ability to form a family through assisted reproduction depends heavily on where you live and what your employer offers — not on any principled account of why this condition warrants less medical attention than others.

It is protecting access to family formation for people whom nature and law have historically excluded. Same-sex couples, single people by choice, and individuals who have undergone medical treatment that affected their fertility have all used IVF and related technologies to build families that could not have existed otherwise. For many of these families, the technology is not a luxury or a philosophical experiment — it is the only path. Opposition to the technology on the grounds that it separates reproduction from the conjugal union, or that it produces children who lack a genetic connection to one or both parents, often translates, in practice, into telling gay couples they cannot have children and telling cancer survivors that chemotherapy's effects on their fertility are simply their cross to bear.

It is protecting the primacy of parental intent over biological definition. The legal and social framework that has grown up around IVF has gradually shifted from defining parenthood by genetics toward defining it by intention and care. This is not a development that happened by accident. It reflects a considered judgment that the parent-child relationship is constituted by commitment, not conception — that the people who chose to bring a child into existence, who prepared for her, who are raising her, are her parents in every sense that matters.

What embryo moral status advocates are protecting

Concern about IVF's routine creation and disposal of human embryos is not confined to religious conservatives, though it is often framed that way. It engages a question that philosophy and law have not resolved: at what point does a human organism acquire the kind of moral status that requires it to be treated as more than a means to someone else's ends? This position has real things to protect.

It is protecting the claim that uncertainty about embryo status should generate caution, not indifference. The President's Council on Bioethics, in Reproduction and Responsibility: The Regulation of New Biotechnologies (2004), argued that the extracorporeal human embryo is a new kind of entity whose moral status is genuinely uncertain. It is not a person in the full legal and social sense; it is also not nothing. The practice of IVF involves the routine creation of surplus embryos, many of which are eventually discarded, destroyed in research, or left frozen indefinitely. The Council's concern was not that IVF should be banned but that society had moved forward with the technology without honestly confronting what it was doing. An estimated 1.5 million frozen embryos are currently stored in the United States. What obligations attend that storage — and what it means when that storage ends — has never been seriously addressed.

It is protecting a foundational claim about when human life deserving protection begins. The Catholic Church's Donum Vitae (1987) and Dignitas Personae (2008) hold that the human embryo possesses full personal dignity from the moment of fertilization — that its creation outside the body for purposes other than immediate transfer to the womb, and especially its creation with the expectation of surplus and discard, treats a person as a raw material. Leon Kass, in "The Wisdom of Repugnance" (The New Republic, 1997), made a secular version of this point: the intuitive revulsion that many people feel at certain reproductive technologies is not mere squeamishness. It is a signal that something morally significant is at stake — and that the imperative to use every available technology to satisfy reproductive desire should not automatically override it.

It is protecting the legal coherence of embryo status from the downstream implications of treating embryos as property. The 2024 Alabama Supreme Court ruling that frozen embryos could constitute "children" under state wrongful death law produced immediate chaos — IVF clinics suspended operations because they could not continue practices that inevitably involve embryo loss without potential criminal liability. The ruling was subsequently legislatively overridden, but it dramatized a genuine structural problem: if embryos are legally persons, the standard practices of IVF are legally impossible. If embryos are legally property, they can be bought, sold, and discarded without any constraint that the people most committed to their significance find tolerable. Neither extreme is satisfying, and the law has so far managed the gap by looking away rather than resolving it.

What genetic selection critics are protecting

Preimplantation genetic testing — the screening of IVF embryos for chromosomal or genetic characteristics before transfer — is now routine in many IVF cycles. The technology is presented as a medical benefit: fewer miscarriages, higher success rates, lower probability of births with serious conditions. A distinct set of critics, including disability rights advocates and bioethicists concerned about the logic of enhancement, see something more troubling. This position has real things to protect.

It is protecting the expressivist claim that selection against a condition sends a message about the value of lives with that condition. Erik Parens and Adrienne Asch, in "The Disability Rights Critique of Prenatal Genetic Testing" (Hastings Center Report, 1999), articulated what became the most influential version of this argument: when parents use prenatal testing to select against a disability, they are not simply choosing a healthier child. They are choosing not to have a child like the ones already living with that condition. The decision, however personal, expresses a judgment — that lives with Down syndrome, or deafness, or spina bifida, are less worth living. That judgment affects the people living those lives: it tells them that the world would prefer they not exist, and it shapes the social and medical environment in ways that affect their actual welfare and inclusion.

It is protecting the stability of the line between treatment and enhancement. Michael Sandel, in The Case Against Perfection: Ethics in the Age of Genetic Engineering (Harvard University Press, 2007), argues that there is something lost when children become objects of design rather than gifts of nature. His concern is not primarily religious. It is that the disposition he calls "giftedness" — the openness to the child you receive, rather than the child you selected — is a condition for the kind of unconditional love that good parenting requires. When selection expands, the temptation to select for everything expands with it: not just the absence of trisomy 21, but height, intelligence, temperament, athletic potential. The logic of optimization does not stop at the threshold of disease. The same platform that screens for chromosomal anomalies is the platform on which, in principle, every heritable characteristic can eventually be selected for or against.

It is protecting a society-level alarm about aggregate patterns that individual choices do not intend. Diane Paul, in Controlling Human Heredity: 1865 to the Present (Humanity Books, 1995), traces how the boundary between voluntary individual reproductive decisions and state-directed eugenics is less stable than it appears. The American eugenics movement of the early twentieth century succeeded not only through compulsory sterilization but through cultural pressure: the social message that certain kinds of people should not reproduce was internalized and acted on voluntarily by many who were never legally coerced. A practice that is individually chosen and privately motivated can still constitute a social pattern with consequences no individual chose. A generation of decisions to screen out Down syndrome is a generation-long statement about who belongs.

What access and equity advocates are protecting

The debate about reproductive technology is rarely framed as a class and race issue. It should be. The technology's distribution across the population — who can access it, who provides the gametes and the gestation, and who the technology has historically been designed to serve — tells a story that intersects with America's deepest inequalities. This position has real things to protect.

It is protecting the recognition that reproductive assistance, like all medicine, reflects and reproduces existing hierarchies. Dorothy Roberts, in Killing the Black Body: Race, Reproduction, and the Meaning of Liberty (Pantheon, 1997), documents the long history of American reproductive policy working against Black women's fertility — through coerced sterilization, welfare conditions, and medical practices that treated Black women's bodies as less worthy of protection or care. The expensive fertility industry that serves predominantly white, upper-income couples does not exist in isolation from that history. It participates in a structure that has always made some people's reproduction a social priority and other people's reproduction a social problem. The politics of whose infertility gets treated — and at what cost — cannot be separated from the politics of whose fertility has been suppressed.

It is protecting the welfare of gamete donors and gestational surrogates who make the technology possible. Egg donation is predominantly performed by young women in financial need who respond to advertisements on college campuses and fertility clinic websites. The physical demands of the process — ovarian hyperstimulation, multiple injections, surgical retrieval — are significant. The long-term health consequences are not fully understood. Compensation structures create financial pressure to participate that cannot be cleanly distinguished from financial coercion. Gestational surrogacy has produced a global industry — documented by Charis Thompson in Making Parents: The Ontological Choreography of Reproductive Technologies (MIT Press, 2005) — in which the bodies of women in low-income countries carry the pregnancies of couples in high-income ones. The language of choice and consent applies unevenly across the enormous economic gradient that separates the people who want children from the people whose bodies they pay to use.

It is protecting the principle that reproductive access, if it is recognized as a right, must be universal and not means-tested. IVF costs between $12,000 and $25,000 per cycle in the United States, with most patients requiring multiple cycles. The resulting median out-of-pocket cost for a successful IVF birth exceeds $50,000. Insurance coverage mandates in nineteen states have expanded access significantly in those states; coverage disparities between states track closely with economic inequality and racial composition. Marcia Inhorn, in Cosmopolitan Conceptions: IVF Sojourners in Global Dubai (Duke University Press, 2015), documents the global traffic in reproductive tourism — patients who travel across borders to access technology, gametes, or surrogacy arrangements unavailable or unaffordable at home. The geography of reproductive access is a map of wealth, citizenship, and racial status. If the ability to form a family through assisted reproduction is genuinely recognized as a right, the current distribution of that ability is a profound injustice.

Where the real disagreement lives

The four positions are not simply arguing about different policies. They are arguing about different questions, often without recognizing that the other positions are not asking what they are asking.

When does a human organism acquire moral status? The embryo moral status position and the reproductive autonomy position are in direct conflict here, but the conflict is between different accounts of what kind of entity an embryo is — an account that cannot be settled by medical fact alone. The embryo's biology is clear. What moral weight to assign it is not. The gap between the position that embryos are persons from fertilization and the position that they are potential persons whose interests matter less than those of the adults who want children is not a gap that more information can close. It is a gap in foundational moral commitments.

Are aggregate social patterns the right level of analysis for individual choices? The expressivist argument and the eugenics- history argument hold that individual reproductive decisions, taken together, constitute social facts with their own moral character — facts that no individual chose and that no individual can be held responsible for, but that are nonetheless real consequences of how the technology is used. Reproductive autonomy advocates resist this framing: to hold individuals responsible for aggregate social messages is to use individual people as instruments of social policy, which is itself a violation of the autonomy principle. The disagreement is not resolvable within either framework. It requires a theory of how individual choices and collective patterns relate — a theory that neither side has fully articulated.

Who is the relevant subject of protection? The four positions have different answers. For reproductive autonomy advocates, it is the person or couple seeking a child. For embryo moral status advocates, it is the embryo. For genetic selection critics, it is the population of living people whose conditions are being screened against. For access and equity advocates, it is gamete donors, surrogates, and lower-income people who cannot access the technology at all. These are not competing claims about the same subject — they are claims about different subjects, which is part of why people talking about reproductive technology often sound as if they are talking past each other. They are.

Is the technology's meaning fixed by its current use, or by where it is heading? IVF as practiced in 1978 did not include genetic screening. IVF as practiced in 2026 routinely does. The trajectory points toward polygenic screening for complex traits, and beyond that toward germline editing — heritable genetic changes that would affect not just the individual but all their descendants. Whether the current technology should be evaluated by what it is now or by what it is becoming is genuinely contested. The reproductive autonomy position tends to evaluate technologies by their present practice; the genetic selection critics evaluate the same technologies by the gradient they are part of.

What sensemaking surfaces

The reproductive technology map is one where political alignments become strange. The Catholic Church and the disability rights movement share a concern about embryo selection and genetic testing, though for reasons with almost nothing else in common — one rooted in the sanctity of all human life from conception, the other rooted in the social construction of disability and the cultural devaluation of difference. Libertarian reproductive autonomy advocates share terrain with LGBT rights advocates and with feminist reproductive rights advocates, though not with the feminist scholars who worry most about egg donation and surrogacy. Access and equity advocates often support IVF coverage mandates while simultaneously critiquing the industry's racial and class structure. These alliances do not form stable coalitions, which is part of why reproductive technology has not produced the same partisan sorting as abortion.

Robertson's procreative liberty framework, the most influential defense of reproductive autonomy, has a particular vulnerability that this map surfaces: it was designed to protect decisions from government interference, but most of what matters about reproductive technology is not primarily a question of government prohibition. It is a question of who pays, who can access, who bears the risks, and what social messages are sent by the aggregate pattern of individual choices. A framework built around the liberty to choose cannot, without significant extension, address what is done to the people whose economic position makes choice constrained or whose lives are being chosen against. The liberty frame answers one question well — should the state prohibit this? — and a different question poorly: is this system, as it operates, just?

The Alabama embryo ruling offered a preview of what it looks like when the law tries to resolve, by decree, a question the society has not actually resolved. The result was not clarification but paralysis: a ruling in which embryos were legally children, combined with a legal framework in which IVF requires routine embryo loss, produced a situation in which practicing medicine was functionally impossible. The legislature's swift override did not answer the underlying question. It deferred it. This is probably the honest position: the society does not know what to do with the frozen embryo, and a ruling that forces a resolution before a consensus exists does not create consensus — it creates backlash and confusion. The question will return.

The pattern that runs through all four positions on reproductive technology is the one Ripple's maps encounter most often in bioethics: the gap between what technology makes possible and what ethical frameworks have caught up with. IVF arrived before the law had a theory of embryo status. Preimplantation genetic testing arrived before bioethics had settled the expressivist debate. Gestational surrogacy arrived before labor law had a theory of reproductive work. At each moment, the technology has moved faster than the social and legal infrastructure that would allow its use to be evaluated clearly. The result is that every position in this debate is, in part, a response to a fait accompli — an argument about a technology that is already in widespread use, that has already produced millions of desired children, that has already created a multibillion-dollar industry — and whose terms of debate are therefore constrained in ways they would not be if the conversation had happened first.